The biopharmaceutical contract manufacturing market in Europe has constantly been through alternating cycles of excess and inadequate manufacturing capacities since the establishment of contract manufacturing organisations (CMOs) in the mid-1990s. The current scenario in Europe indicates a marginally excessive supply of capacity over demand and in the future, surplus supply is expected in the long term. As of 2011 a few CMOs are on the verge of capacity expansions for specific projects, and the demand for outsourcing of biopharmaceutical manufacturing is growing at a rate of 15 per cent.
Although, the current scenario indicates a marginally excessive supply of capacity over demand, there is need for additional capacity requirements in future, given the rich pipeline and growth of biosimilars.
“The European biosimilars market is expected to experience significant growth, as almost half the biologics in this space are set to lose their patent protection over the next 10 years, propelling the need for new capacity additions,” observes Aiswariya Chidambaram, Research Analyst at Frost & Sullivan.
While market opportunities abound for CMOs, the careful outweighing of the risks and the benefits of capacity expansion will be the key to success. “Given the current scenario of surplus capacity supply, it is essential that CMOs make cautious decisions regarding capacity expansion and choice of contract deals, lest they be hit by overcapacity and a subsequent erosion of profit margins, “ says Aiswariya Chidambaram.
In the future, an increasing demand for the outsourcing of the biopharmaceutical manufacturing activities to CMOs is anticipated, especially for crucial operations like upstream and downstream processing and fill and finish activities. Europe holds the best track record for the regulatory approval of biosimilars, a market that is expected to contribute a robust growth rate of 49-55 per cent over the next seven years.
Frost & Sullivan has recently organised an on-demand web-conference entitled “What Underpins the Success of Biopharmaceutical CMOs in Europe”. The web-conference summarises Ms Chidambaram’s findings, investigating the technology landscape and establishing an understanding of the current and future trends in the European Biopharmaceutical Contract Manufacturing Market, thus enabling the market participants to make strategic decisions for the future.
This web-conference will benefit all biopharmaceutical Contract Manufacturing Organizations, pharmaceuticals CMOs, biopharmaceutical companies, pharmaceutical companies and technology providers in the biopharmaceutical industry in Europe as well as manufacturers and companies in various related sectors.
To receive a presentation of the web-conference and a link to the recording, please send an email to Janique Morvan, Corporate Communications, at janique.morvan@frost.com with your full contact details.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEOs Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Contact
Janique Morvan
Corporate Communications – Europe
P: +33 (0) 1 42 81 20 37
M: +33 (0) 6 79 22 41 42
E: janique.morvan@frost.com
http://www.frost.com
